Article Information
History
- September 19, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Muhammad Habiburrahmana,
- Nahal Masroura,
- Naina Patelb,
- Anna M Piskorzc,
- Robert Browna,
- James D Brentonc,
- Iain A McNeisha,e and
- James M Flanagana,*
- aDivision of Cancer, Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, United Kingdom, W12 0NN
- bImperial Experimental Cancer Medicine Centre, Imperial College London, Department of Surgery and Cancer, Imperial College London, London, United Kingdom, W12 0NN
- cCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom, CB2 2RE
- dCambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, CB2 0QQ
- eHammersmith Hospital Imperial College Healthcare NHS Foundation Trust, London, United Kingdom, W12 0HS
- ↵*Corresponding author
Professor James M Flanagan, Division of Cancer, Department of Surgery and Cancer, Imperial College London. Address : 4th Floor IRDB, Hammersmith Campus of Imperial College London, Du Cane Road, London, United Kingdom, W12 0NN, Email address : j.flanagan{at}imperial.ac.uk
Posted September 19, 2024.
Clinical validation of a DNA methylation biomarker to predict overall survival of relapsed ovarian cancer patients
